Scientists are learning a lot about the causes of Alzheimer’s disease and how to possibly treat it before memory problems are present. We know that Alzheimer’s is a slow and gradual disease linked to a buildup of protein in the brain known as amyloid plaque. This impairs memory and thinking as the disease progresses, but scientists are now seeking ways to catch the disease early and prevent the onset of memory loss.
Doctors at NCR are testing new treatments to help stop or slow down brain changes before any symptoms appear. We are currently conducting studies on a new treatment called trontinemab. This medication combines a specialized antibody with a delivery system to help it reach the brain more efficiently and clear out amyloid plaque. These studies are for people who currently have normal memory and thinking in their daily lives, but who carry biological warning signs—such as an elevated pTau217 protein level found through a simple blood test—that put them at risk for Alzheimer’s.
Participants in this study receive either the trontinemab medication or a placebo to compare the effects and see how well the treatment prevents or slows down the development of Alzheimer’s symptoms.
55 – 80 years old
- Have a Study Partner (i.e. a person who interacts with you at least 8 hours each week and is also willing to participate in select study visits)
- No stroke or seizure in the last 12 months
- Willing and able to receive MRI & PET scans
- No current cognitive impairment (MCI) or dementia diagnosis
2 or more years
Varies for the participant and the study partner. The amounts will be outlined in the study consent form provided during your first visit.
Want to participate? Fill out the interest form! Click to Call Us!